Pharmaceutical company Eli Lilly has announced an investment of €35m for a new high-tech manufacturing facility at its Kinsale campus in Co Cork.
The company said the new facility will use pioneering technology that has the potential to transform how medicines are made in the future.
The Kinsale site becoming the centre of excellence for continuous manufacturing for "Active Pharmaceutical Ingredients" for Lilly worldwide when the facility is complete by early 2017.
Eli Lilly's investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
Chris Langan, Eli Lilly's general manager at Kinsale, said the investment builds on the strong technical capability already in place in Kinsale.
"The company is amongst the industry leaders in the development of this technology, and it is an exciting project for everyone involved here at the site," he added.
IDA Ireland's chief executive Martin Shanahan said that pharma companies such as Lilly continue to choose Ireland for a number of reasons.
"One of the main reasons is the world-class pharma infrastructure and skilled workforce in Ireland. This investment demonstrates Lilly’s enduring commitment to Ireland. It also further illustrates Ireland’s position as a leading location for the development and manufacture of pharmaceutical and biopharmaceuticals medicines," Mr Shanahan added.
